Questcor Pharmaceuticals, Inc. has announced that it will be considering its principal product H.P. Acthar for use in a new area – nephrotic syndrome. In this condition, there is excessive spilling of protein into the urine from the kidneys of the patient. Acthar is specifically indicated to deal with this condition (proteinuria). Questcor is in discussions with nephrologists about the possible therapeutic application of Acthar. A broader indication for the product is expected in future.